Comparative analysis of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis - Epidemiology and predictive factors;Análise comparativa entre tuberculose multirresistente e tuberculose extensivamente resistente - Epidemiologia e factores preditivos

Revista Portuguesa de Pneumologia

Volumn 14, Issue 6, 2008, Pages 829-842

  Vilariça, Ana Sofia ^a   Gomes, Carlos ^a   Pina, Jaime ^a  

^a HOSPITAL PULIDO VALENTE   (Portugal)

Author keywords

Epidemiology; Extensively drug resistant tuberculosis (XDR TB); Multidrug resistant tuberculosis (MDR TB); Predictive value

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; QUINOLONE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ALCOHOLISM; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DEPENDENCE; DRUG TREATMENT FAILURE; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LENGTH OF STAY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANCE; RACE DIFFERENCE; RISK FACTOR; TREATMENT DURATION; TUBERCULOSIS;

EID: 60849094830     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0873-2159(15)30289-0     Document Type: Article

References (13)

1. World Health Organization. "WHO Global Task Force outlines measures to combat XDR-TB worldwide". - Geneva, Switzerland, 9-10 October 2006
2. Migliori GB; Besozzi G, Girardi E, et al. Clinical and operational value of extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30(4): 623-6.
3. The Global MDR-TB & XDR-TB Response Plan 2007-2008.
4. Neel RG, Mol A, Sturm A, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 38 (4): 1575-80.
5. Mota P, Diogo N, Pina J. Multi-drug resistant tuberculosis in a respiratory infectious diseases unit - Results from five years. Rev Port Pneumol 2005; 11(6 Suppl 1): 44-5
6. Maltez F, et al. Extensively drug-resistant tuberculosis - case analysis 2003-2007. 17th International AIDS Conference, Mexico City, abstract MOPDB207, 2008.
7. Raviglione MC. Facing Extensively drug-resistant tuberculosis-A hope and a challenge. N Engl J Med 2008; 359(6): 636-8.
8. Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367: 952-5.
9. Caminero J. Likelihood of generating MDR-TB and XDR-TB under National Tuberculosis Control Programme Implementation. Int J Tuberc Lung Dis 2008; 12(8):869-77.
10. Blaas SH, Mutterlein R, Weig J, Neher A, Salzberger B, Lehn N, Naumann L. Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis 2008; 2 (8):60.
11. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S, Flood J. Extensively drug-resistant tuberculosis-California, 1993-2006. Clin Infect Dis 2008; 47(4):450.
12. Jeon CY, Hwang SH, et al. Extensively drug-resistant in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008; 46(1):42-9.
13. CDC. extensively drug-resistant tuberculosis-United States, 1993-2006. MMWR 2007; 56:250-3.